← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 12.6% to $895.6M, while Net income increased 24.8% to $95.2M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $895.6MOK
- Profitability — Net income $95.2MOK
- Cash generation — Free cash flow $91.6MOK
- Accounting — Distress score not computed · no manipulation flag · earnings quality safeNote
- Insiders — 0 buys; 14 sells in 365 daysNote
- Capital — share repurchases were $37.6MNote
Business
CORVEL CORP: We partner with employers, third-party administrators ("TPAs"), insurance companies and government agencies to assist our customers in managing the increasing medical costs of workers' compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants.
Where the revenue comes from
Fiscal 2026, as CORVEL CORP reports it. History and quarterly detail are in the app.
- Patient Management Services$596.7M
- Network Solutions Services$361.8M
Leadership changes
From CORVEL CORP's own filings, the day they're filed.
- Sarah Scott · Chief Executive Officer · appointmenteff. 2026-07-01
- Brian Nichols · Chief Financial Officer · appointmenteff. 2025-09-10
- Michael G. Combs · Chairman · appointmenteff. 2024-11-26
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-05
- DEF 14A · Annual proxy (pay & governance)2026-06-26
- 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CORVEL CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.